


CLAIMS

1. compound of formula I, or a pharmaceutically acceptable salt or ester thereof



In which

R is H, -R₂, -OR₂ or NR₁R₂,

wherein R₁ is H, lower alkyl or C₃ to C₁₀ cycloalkyl, and

R₂ is lower alkyl or C₃ to C₁₀ cycloalkyl, and

wherein R₁ and R₂ are independently, optionally substituted by halo, hydroxy, lower alkoxy, CN, NO₂, or optionally mono- or di-lower alkyl substituted amino;

X is =N- or =C(Z)-,

wherein Z is H, -R₄, -C≡C-CH₂-R₅, C(P)=C(Q)-R₃,

wherein

P and Q independently are H, lower alkyl or aryl,

R₃ is aryl, aryl-lower alkyl, C₃-C₁₀cycloalkyl, C₃-C₁₀cycloalkyl-lower alkyl, heterocyclyl or heterocyclyl-lower alkyl,

wherein R₃ is independently, optionally substituted by one or more groups, e.g. 1-3 groups, selected from halo, hydroxy, oxo, lower alkoxy, CN or NO₂, or optionally substituted (optionally mono- or di-lower alkyl substituted amino, aryl, aryl-lower alkyl, N-heterocyclyl or N-heterocyclyl-lower alkyl (wherein the optional substitution comprises from 1 to 3 substituents selected from halo, hydroxy, lower alkoxy, CN, NO₂, or optionally mono- or di-lower alkyl substituted amino)),

R₄ is H, aryl, aryl-lower alkyl, aryl-lower-alkenyl, C₃-C₁₀cycloalkyl, C₃-C₁₀cycloalkyl-lower alkyl, heterocyclyl or heterocyclyl-lower alkyl, and wherein

R₅ is aryl, aryl-lower alkyl, aryloxy, aroyl or N-heterocyclyl as defined above, and

wherein R₅ is optionally substituted by R₇ which represents from 1 to 5 substituents selected from halo, hydroxy, CN, NO₂ or oxo, or optionally substituted (lower-alkoxy,

lower-alkyl, aryl, aryloxy, aroyl, lower-alkylsulphonyl, arylsulphonyl, optionally mono- or di-lower alkyl substituted amino, or N-heterocyclyl, or N-heterocyclyl-lower alkyl, wherein N-heterocyclyl denotes a saturated, partially unsaturated or aromatic nitrogen containing heterocyclic moiety attached via a nitrogen atom thereof having from 3 to 8 ring atoms optionally containing a further 1, 2 or 3 heteroatoms selected from N, NR₆, O, S, S(O) or S(O)₂ wherein R₆ is H or optionally substituted (lower alkyl, carboxy, acyl (including both lower alkyl acyl, e.g. formyl, acetyl or propionyl, or aryl acyl, e.g. benzoyl), amido, aryl, S(O) or S(O)₂), and wherein the N-heterocyclyl is optionally fused in a bicyclic structure, e.g. with a benzene or pyridine ring, and wherein the N-heterocyclyl is optionally linked in a spiro structure with a 3 to 8 membered cycloalkyl or heterocyclic ring wherein the heterocyclic ring has from 3 to 10 ring members and contains from 1 to 3 heteroatoms selected from N, NR₆, O, S, S(O) or S(O)₂ wherein R₆ is as defined above), and

wherein heterocyclyl denotes a ring having from 3 to 10 ring members and containing from 1 to 3 heteroatoms selected from N, NR₆, O, S, S(O) or S(O)₂ wherein R₆ is as defined above), and

and

wherein R₇ is optionally substituted by from 1 to 3 substituents selected from halo, hydroxy, optionally mono- or di-lower-alkyl substituted amino, lower-alkyl carbonyl, lower-alkoxy or lower-alkylamido;

Y is -NR₈R₉,

wherein

R₈ is H, or optionally substituted (lower alkyl, aryl, aryl-lower alkyl, C₃-C₁₀cycloalkyl, C₃-C₁₀cycloalkyl-lower alkyl, heterocyclyl or heterocyclyl-lower alkyl),

wherein R₈ is optionally substituted by R₁₀ which represents from 1 to 4 substituents selected from halo, hydroxy, CN, NO₂, -O-C(O)-, optionally substituted (lower-alkyl, C₃-C₁₀cycloalkyl, lower-alkoxy, lower-alkenyl, lower-alkynyl, optionally mono- or di-lower alkyl-substituted amino or N-heterocyclyl (as defined above),

wherein R₁₀ is optionally substituted by R₁₁ which represents from 1 to 4 substituents selected from halo, hydroxy, CN, NO₂, oxo, optionally substituted (optionally mono- or

di-lower alkyl-substituted amino, lower alkyl, optionally-lower alkyl substituted COOH, sulphinyl, sulphonyl, or N-heterocyclyl (as defined above))


wherein R11 is optionally substituted by R12 which represents from 1 to 4 substituents selected from halo, hydroxy, CN, NO₂, oxo, hydroxy lower alkyl, C₃-C₁₀cycloalkyl, optionally lower alkyl-substituted carboxy, hydroximine, or N-heterocyclyl as defined above, and

wherein


R9 is independently H, or optionally substituted (lower alkyl, aryl, aryl-lower alkyl, C₃-C₁₀cycloalkyl, C₃-C₁₀cycloalkyl-lower alkyl, heterocyclyl or heterocyclyl-lower alkyl), and

wherein R9 is optionally substituted by halo, hydroxy, oxo, lower alkoxy, CN, NO₂, or optionally mono- or di-lower alkyl substituted amino;

or Z and Y together with the carbon atoms to which they are attached are joined to provide a compound of formula I selected from,



or



wherein

R is as defined above;

R15 is lower-alkyl, C₃-C₁₀cycloalkyl, C₃-C₁₀cycloalkyl-lower alkyl, NR₂₀R₂₁-lower alkyl-, where

T is -O- or a direct bond;

R16 is NR₂₀R₂₁-lower alkyl- or R4, both as defined above,

R20 is H, optionally substituted (lower alkyl, aryl, C₃-C₁₀cycloalkyl, lower alkoxy lower alkyl C₃-C₁₀cycloalkyl-lower alkyl or aryl lower alkyl),


R21 is optionally substituted (lower alkyl, aryl, C₃-C₁₀cycloalkyl, lower alkoxy lower alkyl, C₃-C₁₀cycloalkyl-lower alkyl or aryl-lower alkyl), or

R20 and R21 form an N-heterocyclyl ring as hereinbefore defined,



and wherein R20 or R21 are independently optionally substituted by R23 which which represents from 1 to 3 substituents selected from halo, hydroxy, CN, NO₂, oxo, optionally mono- or di-lower alkyl substituted amino, or optionally substituted (lower-alkoxy, lower-alkyl, lower alkoxy carbonyl, aryl, aryl-lower alkyl, aryl-lower alkenyl, aryloxy, aroyl, alkylsulphonyl, arylsulphonyl or N-heterocyclyl or N-heterocyclyl-lower alkyl (wherein N-heterocyclyl is as defined above));

A is -CH= or -C(O)-, B is -C= or -N-, D is -CH= or -C(O)- and E is -CH= or -N(R1) (where R1 is as defined above).


2. A compound according to claim 1 of formula Ib, Ic, II, or IV or a pharmaceutically acceptable salt or ester thereof



Ib



or




wherein


R8' is H or optionally substituted aryl-lower alkyl

wherein R8' is optionally substituted as defined above for R8, and
the other symbols are as defined above.


3. A compound according to claim 1 or a pharmaceutically acceptable salt or ester thereof selected from a compound of formula VI, VII, VIII or IX



VI




VII



VIII

or




IX


wherein the symbols are as defined above.

4. A compound according to claim 1, or a pharmaceutically acceptable salt or ester thereof, selected from any one of the Examples 1, 11, 12, 13, .
5. A compound according to claim 1 for use as a pharmaceutical.

6. A pharmaceutical composition comprising a compound according to claim 1 as an active ingredient.
7. A method of treating a patient suffering from or susceptible to a disease or medical condition in which cathepsin K is implicated, comprising administering an effective amount of a compound according to claim 1 to the patient.
8. The use of a compound according to claim 1 for the preparation of a medicament for therapeutic or prophylactic treatment of a disease or medical condition in which cathepsin K is implicated.
9. A process for the preparation of a compound of formula I or a salt or ester thereof which comprises
 - i) for the preparation of compounds of formula VI or pharmaceutically acceptable salts or esters thereof




wherein R2 and R15 are as defined above, cyanation of a corresponding 2-halo precursor of formula XIV




wherein R2 and R15 are as defined above and Halo is preferably Cl;

ii) for preparation of compounds of formula VII or pharmaceutically acceptable salts or esters thereof




wherein R2 and R16 are as defined above, coupling of a 6-hydroxy precursor of formula XV with an R16-Halo precursor




wherein R2 and R16 are as defined above and Halo is preferably Cl;

iii) for the preparation of compounds of formula VIII or pharmaceutically acceptable salts or esters thereof.




wherein R2 and R5 are as defined above, coupling of a 5-halopyrimidine precursor of formula XVI with a corresponding R5-CH₂-C≡CH propyne




wherein R2 and R5 are as defined above and Halo is preferably Br;

iv) for the preparation of compounds of formula IX or pharmaceutically acceptable salts or esters thereof



wherein R2 is as defined above and R8'' is optionally substituted aryl-lower alkyl as defined above for R8', coupling of a secondary amine precursor of formula XVII



wherein R2 is as defined above, with a corresponding R8''-Halo precursor, wherein Halo is preferably I;

v) thereafter, if desired, converting the product obtained into a further compound of formula I, or into a salt or ester thereof.

- 10 All novel products, processes and uses substantially as herein described with particular reference to the Examples.